만성 활동성 간질환 환자에서 Diphenyl - Dimethyl - Dicarboxylate 의 혈청 Alanine Aminotransferase 치 저하 효과에 관한 전향적 무작위 선정 대조 연구 = Prospective , Randomiaed , Controlled Trial with Diphenyl - dimethyl - dicarboxylate in Chronic Active Liver Diseases ; The Effect on Lowering Serum Alanine Aminotransferase Levels만성 활동성 간질환 환자에서 Diphenyl - Dimethyl - Dicarboxylate 의 혈청 Alanine Aminotransferase 치 저하 효과에 관한 전향적 무작위 선정 대조 연구

다국어 초록 (Multilingual Abstract)

A prospective randomized controlled trial of a long-term (12 months) therapy with diphenyl-dimethyl- dicarboxlylate (PMC) was performed in a total number of 66 patients with chronic active liver diseases: Thirty one patients received PMC 150 ㎎/d and age, sex-matched 35 patients were enrolled as non-treated controls. Among the 31 patients treated with PMC, PMC was given to 21 patients for 12 months from the start of the study (Group PMC-1) and was given to the rest of 10 patients from the 7th month after 6 months` follow-up period without PMC (Group PMC-2). Serum ALT levels in Group PMC-1 decreased from 192±77 (mean±SD)(U/L) of pre-treatment level to 43±44, 34±38, 23±12, 30±24, 26±16, 29±28, and 27±19 (U/L) at 1st, 2nd, 4th, 6th, 8th, 10th, and 12th month respectively. In contrast, ALT levels of the control patients changed from 180±90 (U/L) of pre-treatment level to 159±100, 159±83, 176±84, 146±67, 115±51, 121±73, and 127±68 (U/L) at 1st, 2nd, 4th, 6th, 8th, 10th, and 12th month respectively. Therefore, there was remarkable difference in the mean ALT levels between Group PMC-1 and control group from the 1st month through to the 12th month (p<0.001). The changes in serum ALT in Group PMC-2 were similar to those of Group PMC-1. However, the difference in the mean serum AST levels between Group PMC-1 and control group were not significant (p>0.05) except for at 4th month (p<0.05). No significant adverse effects were observed except for transient and mild upper gastrointestinal symptoms during PMC treatment.